go-v.orgcodex
Menu
Page tools

codex · Chemistry

BMB-201

BMB-201 is a serotonin 5-HT2A and 5-HT2C receptor agonist of the tryptamine family described as a non-hallucinogenic psychoplastogen which is under development for the treatment of depression, anxiety, pain, and other indications. Its route of administration is unspecified.

== Pharmacology ==

BMB-201 is a prodrug of another compound known as BMB-A39a. This active metabolite acts as a biased partial agonist of the serotonin 5-HT2A and 5-HT2C receptors. BMB-A39a is slightly less efficacious in activating Gq signaling at the serotonin 5-HT2A and 5-HT2C receptors compared to psilocin (EmaxTooltip Maximal efficacy = 68% vs. 82% at 5-HT2A and 79% vs. 95% at 5-HT2C, respectively). It is about 9-fold less potent in activating the serotonin 5-HT2A receptor than psilocin, whereas its potency in activating the serotonin 5-HT2C receptor is similar to that of psilocin.

Relatedly, whereas psilocin shows balanced activation of both the serotonin 5-HT2A and 5-HT2C receptors, BMB-A39a is about 11-fold more potent in activating the serotonin 5-HT2C receptor over the serotonin 5-HT2A receptor. In addition to the serotonin 5-HT2A and 5-HT2C receptors, BMB-A39a is a potent partial agonist of the serotonin 5-HT1F and 5-HT6 receptors. On the other hand, it shows minimal or negligible activity in activating the serotonin 5-HT2B receptor (Emax < 20%), and does not activate other serotonin receptors, for instance the serotonin 5-HT1B and 5-HT1D receptors.

BMB-A39a shows less than 70% efficacy in activating Gq signaling at the serotonin 5-HT2A receptor, which has been associated with absence of hallucinogenic-like activity. Accordingly, BMB-201 is said to have minimal or absent psychedelic effects due to its reduced serotonin 5-HT2A receptor intrinsic activity but to potently induce neuroplasticity. It has been reported to show effectiveness in animal models of depression, anxiety, pain, and substance use disorder.

== Chemistry ==

The exact chemical structure of BMB-201 does not yet appear to have been disclosed. However, it is known to be a tryptamine derivative. In addition, Bright Mind Biosciences has patented tryptamines and prodrugs as serotonin 5-HT2 receptor modulators, including for example 7-methylpsilocin and 7-methylpsilocybin.

== Research == BMB-201 is under development by Bright Minds Biosciences. As of September 2025, it is in the preclinical research stage of development for the treatment of depressive disorders and pain.

== See also == List of investigational hallucinogens and entactogens Substituted tryptamine Non-hallucinogenic 5-HT2A receptor agonist BMB-101 BMB-105 BMB-202 Pharm-136

== References ==

== External links == Pipeline - Bright Minds Biosciences 7-Methylpsilocin - Isomer Design

Wikipedia contributors, "BMB-201", Wikipedia, revision 1368835124, retrieved 21 November 2026, source, CC BY-SA 4.0.

More Chemistry · Search the codex